pmid: 31724441,   nlmid 101150203,  doi:10.1080/14756366.2019.1690480

Inhibition of SARS-CoV 3CL protease by flavonoids.

Jo, Seri Kim, Suwon Shin, Dong Hae Kim, Mi-Sun

Vol. 35, Issue 35, Dec.2020

Journal of enzyme inhibition and medicinal chemistry (J Enzyme Inhib Med Chem),  ISSN 1475-6374


There were severe panics caused by Severe Acute Respiratory Syndrome (SARS) and Middle-East Respiratory Syndrome-Coronavirus. Therefore, researches targeting these viruses have been required. Coronaviruses (CoVs) have been rising targets of some flavonoids. The antiviral activity of some flavonoids against CoVs is presumed directly caused by inhibiting 3C-like protease (3CLpro). Here, we applied a flavonoid library to systematically probe inhibitory compounds against SARS-CoV 3CLpro. Herbacetin, rhoifolin and pectolinarin were found to efficiently block the enzymatic activity of SARS-CoV 3CLpro. The interaction of the three flavonoids was confirmed using a tryptophan-based fluorescence method, too. An induced-fit docking analysis indicated that S1, S2 and S3' sites are involved in binding with flavonoids. The comparison with previous studies showed that Triton X-100 played a critical role in objecting false positive or overestimated inhibitory activity of flavonoids. With the systematic analysis, the three flavonoids are suggested to be templates to design functionally improved inhibitors.

MESH Headings

Article Keywords

FRET | SARS-CoV | SARS-CoV 3CLpro | flavonoid | inhibitory compounds |


Similar Articles

Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs.
Lin, Cheng-Wen Tsai, Chang-Hai Tsai, Fuu-Jen Chen, Pei-Jer Lai, Chien-Chen Wan, Lei Chiu, Hua-Hao Lin, Kuan-Hsun
FEBS letters ,vol(574), issue(1-3),  Sep.2004

Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors.
Jo, Seri Kim, Hyojin Kim, Suwon Shin, Dong Hae Kim, Mi-Sun
Chemical biology & drug design ,vol(94), issue(6),  Dec.2019

Prediction and biochemical analysis of putative cleavage sites of the 3C-like protease of Middle East respiratory syndrome coronavirus.
Wu, Andong Wang, Yi Zeng, Cong Huang, Xingyu Xu, Shan Su, Ceyang Wang, Min Chen, Yu Guo, Deyin
Virus research ,vol(208), issue(),  Oct.2015

Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro.
Niu, Chunying Yin, Jiang Zhang, Jianmin Vederas, John C James, Michael N G
Bioorganic & medicinal chemistry ,vol(16), issue(1),  Jan.2008

Preparation and characterization of monoclonal antibodies against S1 domain at N-terminal residues 249 to 667 of SARS-associated coronavirus S1 protein.
Wen, Kun Mei, Ya-bo Qiu, Li-wen Liao, Zhi-yong Yuen, Kwok-yung Che, Xiao-yan
Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA ,vol(24), issue(1),  Jan.2004

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
Coleman, Christopher M Liu, Ye V Mu, Haiyan Taylor, Justin K Massare, Michael Flyer, David C Smith, Gale E Frieman, Matthew B
Vaccine ,vol(32), issue(26),  May.2014

Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.
Deng, Xufang StJohn, Sarah E Osswald, Heather L O'Brien, Amornrat Banach, Bridget S Sleeman, Katrina Ghosh, Arun K Mesecar, Andrew D Baker, Susan C
Journal of virology ,vol(88), issue(20),  Oct.2014

Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein.
Chang, Chung-ke Lo, Shou-Chen Wang, Yong-Sheng Hou, Ming-Hon
Drug discovery today ,vol(21), issue(4),  Apr.2016

Origin and evolution of pathogenic coronaviruses.
Cui, Jie Li, Fang Shi, Zheng-Li
Nature reviews. Microbiology ,vol(17), issue(3),  Mar.2019

Broad-spectrum coronavirus antiviral drug discovery.
Totura, Allison L Bavari, Sina
Expert opinion on drug discovery ,vol(14), issue(4),  Apr.2019

Medline data is available here.

The Search Enterprise

Contact Us